Acute coronary syndromes and atherosclerotic plaque burden distribution in coronary arteries among patients with valvular heart disease (BIA-WAD registry)

Łukasz Kuźma1, Hanna Bachórzewska-Gajewska1,2, Marcin Kożuch1, Krzysztof Struniawski1, Szymon Pogorzelski1, Tomasz Hirnle1, Sławomir Dobrzycki1

1Department of Invasive Cardiology, Medical University of Bialystok, Bialystok, Poland
2Department of Clinical Medicine, Medical University of Bialystok, Bialystok, Poland
3Department of Cardiac Surgery, Medical University of Bialystok, Bialystok, Poland

Adv Interv Cardiol 2019; 15, 4 (58): 422–430
DOI: https://doi.org/10.5114/aic.2019.90216

Abstract
Introduction: Valvular heart diseases (VHD) are a significant problem in the Polish population. Coexistence of coronary artery disease (CAD) in patients with VHD increases the risk of death and affects the further therapeutic strategy.

Aim: Analysis of atherosclerotic plaque burden distribution in coronary arteries and long-term prognosis among patients with VHD.

Material and methods: Inclusion criteria were met by 1025 patients with moderate and severe VHD. Mean observation time was 2528 ±1454 days.

Results: Severe aortic valve stenosis (AVS) occurred in 28.2%, severe mitral valve insufficiency (MVI) in 20%. CAD with severe angiographic stenoses was noted in 42.3% (n = 434). Among patients with severe MVI, CAD was noted in 47.1% of cases, and prior acute coronary syndromes (ACS) in 27.1% of patients (n = 58). In severe AVS patients, significant angiographic atherosclerotic changes were observed in 29.6% (n = 86), and prior ACS in 7.6% (n = 22) of patients. During the observation 52.7% of patients died, including 62.9% of patients with severe MVI and 51.6% of those with severe AVS. Age (OR = 1.038; 95% CI: 1.005–1.072; p = 0.022) and coexisting aortic valve insufficiency (AVI) (OR = 2.39, 95% CI: 5.370–11.065, p = 0.035) increased the mortality rate.

Conclusions: Severe AVS is starting to be the most prevalent VHD. CAD is one of the most significant factors deteriorating prognosis of patients with VHD. AVI and age were significant risk factors for mortality. The worst prognosis was observed in severe MVI, which may result from more frequent occurrence of CAD in this group. A lesser burden of CAD and ACS in the group of patients with severe AVS did not affect survival.

Key words: aortic stenosis, mitral insufficiency, coronary artery disease, myocardial infarction.

Summary
Coexistence of coronary artery disease (CAD) in patients with valvular heart diseases (VHD) increases the risk of death and affects the further therapeutic strategy. Patients with mitral valve insufficiency are most burdened with CAD and prior acute coronary syndrome. Coexistence of coronary artery disease in patients with VHD increases the risk of death and has an influence on the choice of therapeutic strategy.

Introduction
Cardiovascular diseases are responsible for 46% of deaths in the Polish population despite the constantly developing progress in medical sciences [1]. The most common cardiovascular disorders are coronary artery disease, including acute coronary syndromes, and valvular heart disease (VHD), the frequency of which has been growing continuously in recent years. The greatest increase in prevalence is observed for aortic stenosis (AVS), whereas the number of mitral stenosis cases (MVS) has dropped significantly [2, 3]. This association was reported...
in both national and global registries. The European Registry of Valvular Heart Diseases contains records of 5001 patients from 92 centers from 25 countries. The analysis includes patients in moderate and severe grading of valvular heart disease. The most frequently occurring disease is aortic stenosis (33.9%) and mitral insufficiency (MVI) (24.8%). In the largest Polish registry, WAD-POL, containing 1663 patients; aortic stenosis was found in 27.5%, and mitral regurgitation in 38.0% of the population [4]. The reason for the prevalence of aortic valve stenosis patients stems from the degenerative etiology of the disease [5]. Demographic analyses considering dynamic aging of the Polish society show that there will be nearly 200,000 more elderly in the third decade of the 21st century [6]. The population’s longer survival rate corresponds with an increased percentage of valvular heart diseases of degenerative etiology and worse prognosis of those with coexisting diseases such as coronary artery disease (CAD) or myocardial infarction. Not only does coronary artery disease have similar risk factors as aortic stenosis, but also it is of degenerative and atherosclerotic etiology. Therefore, it is not surprising that advanced coronary artery disease often coexists with valvular heart diseases. Moreover, such patients have a history of acute coronary syndrome (ACS), which has a particular influence on the choice of therapeutic strategy.

Until the beginning of the 21st century, conventional cardiosurgical methods such as valve replacement (VR) were a standard treatment for patients with valvular heart diseases, yet only within the last 10 years have they gradually been substituted by low-invasive techniques. The most widespread procedure is transcatheter aortic valve implantation (TAVI), while a non-surgical approach for mitral regurgitation treatment is also being introduced [7–9]. These methods are particularly indicated in high-risk patients, providing better prognosis.

Taking into consideration insufficient data of patients with coronary artery disease and valvular heart disease, this study provides information of mentioned subjects.

**Aim**

Analysis of atherosclerotic plaque burden distribution in coronary arteries and long-term prognosis among patients with valvular heart disease.

**Material and methods**

Medical records of 12 954 patients hospitalized in the Department of Invasive Cardiology of the Medical University of Białystok in 2006–2010 were analyzed. 1025 patients with moderate and severe valvular heart disease met the inclusion criteria.

Assignment of patients to particular groups was based on the ESC guidelines for the management of valvular heart disease published in 2012 [5]. Prior cardiosurgical valve replacement was the exclusion criterion.

The set of variables subjected to interpretation consisted of demographic data, medical history, coronary angiography, percutaneous and surgical treatment. Follow-up study included the analysis of medical documentation of the Cardiosurgery Department and the Invasive Cardiology Department of the Medical University of Białystok, phone call interview and provided information on the duration and type of procedure performed. There was no follow-up concerning the aforementioned data in 26 (2.5%) cases. All-cause mortality was collected from the Polish Ministry of Digital Affairs on 09.11.2018. The mean follow-up period from the onset to the procedure was 360 ±796 days, and that from the cardiosurgical procedure to death was 2480 ±1445 days. Complete follow-up duration was 2528 ±1454 days.

The study was approved by the Local Bioethics Committee of the Medical University of Białystok no. R-I-002/20/2013.

**Statistical analysis**

Distribution of the variables was assessed with the Kolmogorov-Smirnov test. Student’s t-test was applied for comparative analysis of continuous variables. Evaluation of differences between dichotomic variables was performed using the χ² test. The Wald test for logistic regression was used to determine mortality risk factors. P < 0.05 was considered statistically significant.

**Results**

One hundred and twenty-five patients with moderate and severe valvular heart disease were included in the study. The mean age of the study population was 67.1 ±10.3 years, mostly male (56.6%) (Table I). Aortic valve stenosis was the most common defect and occurred in 28.2% of studied subjects (n = 289), while severe mitral regurgitation was found in 210 (20.5%) patients. Severe aortic regurgitation and severe aortic stenosis occurred in a similar percentage and affected 8% of patients. The most prevalent severe, combined valve disease was co-existing aortic valve stenosis and mitral valve insufficiency (n = 13). The remaining severe multivalve disorders were found in single cases (Tables I and II).

Coronary artery disease occurred in 73.4% of the subjects (n = 752), significant angiographic stenoses were noted in 42.3% (n = 434) of patients, including the left anterior descending artery (LAD) 24.9% (n = 256), left circumflex artery (Cx) 23.0% (n = 236) and right coronary artery (RCA) 22.9% (n = 235). Significant atherosclerotic lesions in the left main coronary artery (LM) were observed in 4.1% of patients (n = 42) (Figure 1). In the group with severe MVI, coronary artery disease was found in 47.1% of cases, and prior acute coronary syndrome in 27.1% of patients (n = 58). In the group with severe AVS, significant angiographic atherosclerotic changes were observed in 29.6% (n = 86) and prior ACS in 7.6%
of patients (n = 22) (Table II). The percutaneous coronary intervention (PCI) was performed in 22.9% of patients (n = 227), with PCI of Cx in 13.2% (n = 136), and PCI of LAD in 11.2% (Table III).

Fifty-four percent of patients underwent cardiac valvular surgery (n = 539). Thirty percent of these procedures were combined with coronary artery bypass grafting. TAVI was performed in 3.2% of severe aortic stenosis patients. Seventy-four subjects underwent PCI during follow-up (7.4%) (Table IV).

52.7% (n = 540) of patients died during follow-up; 62.9% of them (n = 132) had severe mitral regurgitation, 78.6% (n = 33) significant stenosis of the left main coronary artery and 72.4% (n = 92) had a history of non-ST elevation myocardial infarction. 43.6% of patients who underwent cardiac surgery died compared to 68% who did not have surgery. Interestingly, 17 deaths were reported within the first 14 days of inclusion in the study, 6 of which concerned subjects who underwent surgery (Figure 2).

Multivariate regression analysis – the Wald test – determined aortic regurgitation as the most significant risk factor for mortality (Nagelkerke R² = 0.759; overall prediction rate 90.1%). AVI increased the mortality rate 2.4-fold (OR = 2.39; 95% CI: 5.370–11.065; p = 0.035). An increase of age by 1 year raised the risk of mortality by 0.4% (OR = 1.038; 95% CI: 1.005–1.072; p = 0.022). The adjusted hazard ratio for death with follow-up prolongation of 1 year was 2.8 (OR = 2.815; 95% CI: 2.247–3.526; p = 0.001) and coronary artery disease without diagonal stenosis was 0.204 (OR = 0.204; 95% CI: 0.075–0.561; p = 0.002).

**Discussion**

Distribution of gender in the population of the Podlaskie Voivodeship has been unchanged for years. In 2016, men constituted 48.7% of the Podlaskie Voivodeship’s population [10]. In the studied group, the percentage is higher, 56.6% (n = 579), which could be attributed to the fact that male sex is an independent risk factor for the development of degenerative valvular heart disease, coronary artery disease and acute coronary syndrome (Table I). The mean age of the study subjects was 67.1 ±10.1 years, which corresponds to the contemporary medical data, according to which, with the declining rheumatoid etiology of the disease the dominant causes of valvular disease are the degenerative processes associated with old age [11]. This is confirmed by comparative analysis of patients with individual valvular diseases; patients with severe aortic stenosis were older than other patients, 68.1 ±10.4 vs. 66.2 ±9.9, p < 0.001, while patients with mitral stenosis, the dominant background of which is rheumatoid processes, were significantly younger, 62.0 ±9.4 vs. 67.0 ±10.1, p = 0.01. A significantly lower percentage of men was also present in this group, 36.0% (n = 9) vs. 57.6% (n = 570), p = 0.006 (Table II).

Changing etiology contributes to a different epidemiology of valvular heart diseases. In the studied group, mi-

### Table I. Valvular heart disease and coronary artery disease in the analyzed population

| Parameter | All patients (N = 1025) | Patients with aortic stenosis (N = 411) | Patients with aortic insufficiency (N = 194) | Patients with mitral stenosis (N = 74) | Patients with mitral insufficiency (N = 531) |
|-----------|------------------------|----------------------------------------|------------------------------------------|--------------------------------------|--------------------------------------------|
| Age       | 67.1 (SD = 10.1)       | 68.0 (SD = 10.1)                       | 64.1 (SD = 10.4)                         | 64.7 (SD = 9.1)                      | 67.2 (SD = 10.1)                           |
| Male      | 56.7% (N = 579)        | 58.2% (N = 239)                        | 64.6% (N = 122)                         | 24.3% (N = 18)                       | 56.7% (N = 301)                           |
| Moderate VHD | 60.9% (N = 624)      | 29.7% (N = 122)                        | 79.9% (N = 155)                         | 55.4% (N = 41)                       | 60.5% (N = 321)                           |
| Severe VHD | 53.6% (N = 549)       | 70.3% (N = 289)                        | 20.6% (N = 39)                          | 44.6% (N = 33)                       | 39.5% (N = 210)                           |
| Isolated severe VHD | 42.0% (N = 431)    | 49.4% (N = 203)                        | 13.4% (N = 26)                          | 21.6% (N = 16)                       | 31.6% (N = 168)                           |
| Multiple VHD | 25.8% (N = 264)      | 20.0% (N = 82)                         | 35.6% (N = 69)                          | 37.8% (N = 28)                       | 23.6% (N = 125)                           |
| CAD without significant stenosis | 31.0% (N = 318) | 31.1% (N = 128)                        | 30.7% (N = 58)                          | 39.2% (N = 29)                       | 21.5% (N = 114)                           |
| CAD with significant stenosis | 42.4% (N = 434) | 36.5% (N = 150)                        | 34.4% (N = 65)                          | 17.6% (N = 13)                       | 50.1% (N = 266)                           |
| SVD       | 14.4% (N = 147)       | 13.9% (N = 57)                         | 14.8% (N = 28)                          | 9.5% (N = 7)                         | 15.3% (N = 81)                            |
| MVD       | 28.0% (N = 287)       | 22.6% (N = 93)                         | 19.6% (N = 37)                          | 8.1% (N = 6)                         | 34.8% (N = 185)                           |
| ACS       | 21.6% (N = 223)       | 10.7% (N = 44)                         | 13.2% (N = 25)                          | 5.4% (N = 4)                         | 31.6% (N = 168)                           |
| STEMI     | 9.4% (N = 96)         | 6.8% (N = 28)                          | 8.5% (N = 16)                           | 2.7% (N = 2)                         | 17.3% (N = 92)                            |
| NSTEMI    | 12.4% (N = 127)       | 3.9% (N = 16)                          | 4.8% (N = 9)                            | 2.7% (N = 2)                         | 14.3% (N = 76)                            |
| Death     | 52.7% (N = 540)       | 54.0% (N = 222)                        | 43.4% (N = 82)                          | 43.2% (N = 32)                       | 57.4% (N = 305)                           |

ACS – acute coronary syndrome, CAD – coronary artery disease, MVD – multi-vessel disease, NSTEMI – non-ST elevation myocardial infarction, SVD – single-vessel disease, STEMI – ST elevation myocardial infarction, VHD – valvular heart disease.
Table II. Coronary artery disease in patients with severe valvular heart disease

| Parameter | Patients with severe VHD (N = 549) | Patients with multiple severe AVS/MVI VHD (N = 260) | P-value | Patients with severe AVS (N = 289) | Other patients with severe VHD (N = 281) | P-value | Patients with severe AVI (N = 39) | Other patients with severe VHD (N = 260) | P-value | Patients with severe MVS (N = 33) | Other patients with severe VHD (N = 284) | P-value | Patients with severe MVI (N = 210) | Other patients with severe VHD (N = 339) | P-value |
|-----------|-----------------------------------|-----------------------------------------------|---------|-----------------------------------|-----------------------------------------|---------|-----------------------------------|-----------------------------------------|---------|----------------------------------|-----------------------------------------|---------|-----------------------------------|-----------------------------------------|---------|
| Male      | 53.5% (N = 293)                  | 85.6% (N = 12)                               | 0.005   | 53.6% (N = 155)                  | 53.1% (N = 138)                           | 0.5     | 74.4% (N = 29)                   | 53.5% (N = 293)                           | 0.004   | 36.0% (N = 9)                     | 55.0% (N = 284)                           | < 0.001 | 61.2% (N = 104)                   | 55.7% (N = 189)                           | 0.5     |
| Age       | 67.0 (SD = 10.2)                 | 71.7 (SD = 10.4)                             | 0.034   | 68.1 (SD = 10.4)                 | 66.2 (SD = 9.9)                           | < 0.001 | 58.0 (SD = 9.6)                  | 67.0 (SD = 9.7)                           | < 0.001 | 62.0 (SD = 9.4)                   | 67.0 (SD = 10.1)                          | 0.006   | 67.3 (SD = 9.1)                   | 66.0 (SD = 10.3)                          | 0.4     |
| CAD       | 30.0% (N = 167)                  | 35.8% (N = 162)                             | 0.3     | 29.6% (N = 86)                  | 31.1% (N = 81)                           | 0.1     | 20.0% (N = 8)                   | 31.2% (N = 159)                           | 0.3     | 6.1% (N = 2)                      | 31.9% (N = 165)                           | 0.018   | 47.1% (N = 99)                    | 20.1% (N = 68)                            | < 0.001 |
| SVD       | 13.1% (N = 72)                  | 0.0% (N = 0)                                | < 0.001 | 12.4% (N = 36)                  | 13.8% (N = 36)                           | 1.0     | 15.6% (N = 6)                   | 12.9% (N = 66)                           | 0.7     | 6.1% (N = 2)                      | 13.6% (N = 70)                           | 0.1     | 13.8% (N = 29)                    | 12.7% (N = 43)                            | 0.7     |
| MVD       | 21.7% (N = 119)                  | 21.4% (N = 116)                             | 1.0     | 17.3% (N = 136)                 | 26.5% (N = 69)                           | 0.008   | 8.0% (N = 2)                    | 22.9% (N = 117)                           | < 0.001 | 0.0% (N = 0)                      | 23.0% (N = 119)                           | < 0.001 | 33.4% (N = 70)                    | 14.5% (N = 49)                            | < 0.001 |
| ACS       | 15.1% (N = 83)                  | 0.0% (N = 0)                                | 0.1     | 7.6% (N = 83)                  | 23.5% (N = 61)                           | < 0.001 | 7.7% (N = 2)                    | 15.7% (N = 80)                           | 0.1     | 0.0% (N = 0)                      | 16.1% (N = 83)                           | < 0.001 | 27.1% (N = 58)                    | 7.4% (N = 25)                             | < 0.001 |
| STEMI     | 6.6% (N = 36)                   | 0.0% (N = 0)                                | < 0.001 | 2.4% (N = 36)                  | 11.1% (N = 29)                           | < 0.001 | 5.1% (N = 3)                    | 6.7% (N = 34)                            | 0.7     | 0.0% (N = 0)                      | 6.9% (N = 36)                            | < 0.001 | 12.9% (N = 27)                    | 2.7% (N = 9)                              | < 0.001 |
| NSTEMI    | 8.6% (N = 47)                   | 0.0% (N = 0)                                | 0.2     | 5.2% (N = 47)                  | 12.3% (N = 45)                           | < 0.001 | 2.6% (N = 1)                    | 9.0% (N = 46)                            | 0.027   | 0.0% (N = 0)                      | 9.1% (N = 47)                            | < 0.001 | 14.7% (N = 31)                    | 4.7% (N = 16)                             | < 0.001 |
| Death     | 53.3% (N = 292)                  | 65.3% (N = 283)                             | 0.4     | 51.6% (N = 283)                 | 55.1% (N = 142)                          | 0.3     | 30.7% (N = 12)                   | 54.9% (N = 280)                           | 0.003   | 42.4% (N = 14)                    | 53.9% (N = 278)                           | 0.2     | 62.9% (N = 132)                   | 47.2% (N = 160)                           | < 0.001 |

AVI – aortic valve insufficiency, AVS – aortic valve stenosis, CAD – coronary artery disease, MVI – mitral valve insufficiency, MVS – mitral valve stenosis, NSTEMI – non-ST elevation myocardial infarction, SVD – single-vessel disease, MVD – multi-vessel disease, STEMI – ST elevation myocardial infarction, VHD – valvular heart disease.
Atherosclerotic plaque burden in patients with VHD

Łukasz Kuźma et al.

Advances in Interventional Cardiology 2019; 15, 4 (58)

Figure 1. Valvular heart diseases in the study population

Central regurgitation was present in nearly 50% of patients (n = 531). The most prevalent severe valvular disease was aortic stenosis, which occurred in 28.2% of the subjects (n = 289). Similar findings have also been reported in other European studies. In the Euro Heart Survey on Valvular Heart Disease registry, which focused on moderate and severe grades of valvular heart diseases, aortic disease occurred in 44% of patients, with aortic valve stenosis accounting for 34% of cases. Mitral valve regurgitation occurred in 25% of patients, and combined mitral disease in 34% [3]. The WadPol Registry of Heart Diseases, the largest Polish registry of valvular diseases, includes the history of 1663 patients with acquired valvular heart disease in 2007–2008. The most prevalent one was mitral regurgitation, 38% of cases, and aortic valve stenosis was found in 27.5% of patients [4]. The analysis of the valvular diseases etiology revealed the dominance of degenerative over rheumatoid etiology of aortic valve diseases, 50.2% vs. 30.6%. Mitral valve disease presented a similar etiology pattern, with a degenerative background in 41.2% of patients, and rheumatoid etiology in every third patient (30.7%).

In the analyzed group, coronary artery disease occurred in 74.4% (n = 752), whereas significant angiographic stenoses were observed in 42.3% (n = 434) of patients. The lesions were most commonly found in left anterior descending artery (24.9%, n = 256), followed by circumflex artery 23.0% (n = 236) and right coronary artery 22.9% (n = 235). Left main coronary artery was the least affected, 4.1% (n = 42) (Table III). Mentioned findings of the atherosclerotic changes in epicardial coronary arteries are similar to the reports in the current literature. The majority of publications on the topography of coronary artery lesions focus on the greater involvement of the left coronary artery in comparison to the right, which is confirmed by numerous autopsy and angiographic studies. LAD is more often affected by atherosclerotic changes and calcifications than RCA and CX [12]. Similar data are presented in studies evaluating coronary artery calcium score, confirming the predominance of atherosclerosis in LAD, followed by the RCA, CX and LM [13]. In a retrospective analysis of over 13,000 coronary angiographies, an isolated change in RCA was found in 6.5% of cases, while a similar lesion was present over five times more frequently in the left artery (34.7%) [14–17]. Enrico et al. in a study of 73,282 deposits in angio-CT scans of coronary arteries presented similar results by showing that nearly half of them were located in the LAD, and every third in RCA and circumflex artery [18–20]. The analysis also showed that patients with severe aortic stenosis were less often diagnosed with coronary artery disease, which concerned both patients with ischemic heart disease with and without significant atherosclerotic lesions, as well as with multi-vessel disease, 17.3% (n = 50) vs. 26.5% (n = 69), p < 0.001 (including prior STEMI and NSTEMI), 7.6% (n = 22) vs. 23.5% (n = 61), p < 0.001 (Table IV). Significant atherosclerotic changes in epicardial coronary arteries were less common in all coronary arteries in comparison to the group with other valve defects, whereas the majority of lesions were found in LAD, 17.6% (n = 51). The lower prevalence of coronary disease is also reflected in the analysis of invasive treatment. 9.4% of patients with severe aortic stenosis underwent PCI in comparison to 18.8% of patients with other valvular diseases (p < 0.001) (Table III). The lower number of PCIs in this group stemmed from the need for valvular surgery, which was combined with surgical revascularization. Valvular cardiac surgery was performed in 81.3% of patients with severe aortic stenosis and only in 38.4% of patients with other valvular diseases (p < 0.001) (Table IV). These results contradict the hypothesis of a similar pathomechanism and similar risk factors of coronary disease and aortic valve stenosis.

Patients with severe aortic regurgitation had lower prevalence of coronary artery disease with significant atherosclerotic stenoses (20.5% vs. 35.7%, p < 0.03), and acute coronary syndrome, 7.7% (n = 3) vs. 15.7% (n = 80), p = 0.1. Small size of the group and low prevalence of coronary artery disease resulted in a lower number of percutaneous coronary interventions and combined procedures (Table IV).

Similar observations were made for the group of patients with severe mitral stenosis. A moderate grade of the disease occurred in only 4% of patients (n = 41) (Figure 1). This group was significantly younger in comparison with other patients, and it was also the only group with the majority of women, with the coexistence of coronary artery disease and acute coronary syndrome noted in individual cases.

Patients with mitral valve insufficiency made up 52% of the study population, and the subgroup of patients
| Parameter | Patients with severe VHD (N = 549) | Patients with multi-severe AVS/MVI VHD (N = 289) | Other patients with severe VHD (N = 260) | P-value | Patients with severe AVS (N = 39) | Other patients with severe AVS (N = 105) | P-value | Patients with severe MVS (N = 33) | Other patients with severe MVS (N = 182) | P-value | Patients with severe MVI (N = 210) | Other patients with severe MVI (N = 339) | P-value |
|-----------|-----------------------------------|-----------------------------------------------|----------------------------------------|---------|-----------------------------------|------------------------------------------|---------|-----------------------------------|------------------------------------------|---------|-----------------------------------|------------------------------------------|---------|
| CAD²      | 34.9% (N = 191)                  | 21.4% (N = 39)                                | 35.2% (N = 188)                       | 0.017   | 29.6% (N = 86)                    | 40.4% (N = 105)                          | 0.021   | 20.5% (N = 2)                      | 35.7% (N = 182)                         | 0.03    | 6.1% (N = 389)                     | 36.6% (N = 39)                           | < 0.001 |
| PCI²      | 13.9% (N = 76)                   | 14.2% (N = 22)                                | < 0.001                               | 0.03    | 9.4% (N = 27)                     | 18.1% (N = 49)                           | 0.006   | 2.6% (N = 4)                       | 14.7% (N = 75)                         | < 0.001 | 3.0% (N = 1)                       | 14.5% (N = 75)                           | < 0.001 |
| LM³       | 3.1% (N = 17)                    | 3.2% (N = 17)                                 | < 0.001                               | 0.06    | 2.8% (N = 8)                      | 3.5% (N = 9)                             | 0.8     | 2.5% (N = 4)                       | 3.1% (N = 16)                          | 0.8     | 0.0% (N = 5)                       | 2.7% (N = 17)                            | < 0.001 |
| PCI/LM³   | 0.3% (N = 3)                     | 0.5% (N = 3)                                  | 0.1                                    | 0.0%    | 0.7% (N = 2)                      | 0.4% (N = 1)                             | 0.6     | 0.0% (N = 3)                       | 0.5% (N = 3)                           | 0.1     | 0.0% (N = 5)                       | 0.5% (N = 3)                             | < 0.001 |
| LAD       | 19.8% (N = 109)                  | 14.3% (N = 107)                               | 20.0% (N = 51)                        | 0.03    | 17.6% (N = 53)                    | 22.3% (N = 58)                           | 0.2     | 10.0% (N = 2)                      | 20.6% (N = 105)                        | 0.1     | 0.0% (N = 5)                       | 21.1% (N = 109)                          | < 0.001 |
| PCI/LAD   | 6.8% (N = 36)                    | 6.7% (N = 36)                                 | < 0.001                               | 0.01    | 5.9% (N = 17)                     | 7.3% (N = 19)                            | 0.7     | 0.0% (N = 4)                       | 7.1% (N = 36)                          | < 0.001 | 0.0% (N = 3)                       | 6.9% (N = 36)                            | < 0.001 |
| RCA       | 17.0% (N = 93)                   | 16.9% (N = 90)                                | 0.7                                    | 0.02    | 14.8% (N = 40)                    | 20.4% (N = 53)                           | 0.028   | 5.0% (N = 2)                       | 17.8% (N = 91)                         | 0.002   | 3.0% (N = 51)                      | 17.9% (N = 92)                           | < 0.001 |
| PCI/RCA   | 4.9% (N = 27)                    | 5.1% (N = 27)                                 | < 0.001                               | 0.05    | 3.4% (N = 30)                     | 6.5% (N = 37)                            | 0.2     | 0.0% (N = 27)                      | 5.3% (N = 91)                          | < 0.001 | 3.0% (N = 51)                      | 5.0% (N = 92)                            | < 0.001 |
| Cx        | 18.7% (N = 103)                  | 14.3% (N = 101)                               | 18.9% (N = 55)                        | 0.05    | 16.6% (N = 48)                    | 21.2% (N = 55)                           | 0.2     | 7.7% (N = 3)                       | 19.6% (N = 100)                        | 0.013   | 3.0% (N = 102)                     | 19.8% (N = 102)                          | < 0.001 |
| PCI/Cx    | 9.3% (N = 51)                    | 9.6% (N = 51)                                 | 9.6% (N = 36)                         | 0.04    | 5.2% (N = 15)                     | 13.8% (N = 36)                           | 0.004   | 2.6% (N = 4)                       | 9.8% (N = 50)                          | 0.016   | 0.0% (N = 5)                       | 9.8% (N = 51)                            | < 0.001 |
| Diag      | 7.5% (N = 41)                    | 7.7% (N = 41)                                 | < 0.001                               | 0.01    | 3.8% (N = 11)                     | 11.5% (N = 30)                           | 0.002   | 0.0% (N = 11)                      | 8.0% (N = 41)                          | < 0.001 | 0.0% (N = 41)                      | 7.5% (N = 41)                            | < 0.001 |
| PCI/Diag  | 1.5% (N = 8)                     | 1.5% (N = 8)                                  | 0.005                                 | 0.03    | 0.0% (N = 3)                      | 2.7% (N = 7)                             | 0.003   | 0.0% (N = 8)                       | 1.6% (N = 8)                           | < 0.001 | 0.0% (N = 42)                      | 7.9% (N = 42)                            | < 0.001 |
| OM        | 7.7% (N = 42)                    | 7.9% (N = 42)                                 | < 0.001                               | 0.03    | 6.9% (N = 20)                     | 5.7% (N = 35)                            | 0.7     | 0.0% (N = 42)                      | 8.1% (N = 42)                          | < 0.001 | 0.0% (N = 42)                      | 7.9% (N = 42)                            | < 0.001 |
| PCI/OM    | 2.9% (N = 16)                    | 2.9% (N = 16)                                 | < 0.001                               | 0.01    | 2.0% (N = 6)                      | 3.8% (N = 16)                            | 0.3     | 0.0% (N = 16)                      | 3.1% (N = 16)                          | < 0.001 | 0.0% (N = 10)                      | 3.1% (N = 10)                            | < 0.001 |

¹Number of patients with CAD; ²number of patients undergoing PCI; ³number of lesions; ⁴number of procedures; AVI – aortic valve insufficiency; AVS – aortic valve stenosis; CAD – coronary artery disease; Cx – circumflex artery; Diag – diagonal artery; LAD – left anterior descending; LM – left main artery; MVI – mitral valve insufficiency; MVS – mitral valve stenosis; OM – left marginal artery; RCA – right coronary artery; PCI – percutaneous coronary interventions; VHD – valvular heart disease.

Łukasz Kuźma et al. Atherosclerotic plaque burden in patients with VHD.
with severe insufficiency accounted for 20.5% (Tables I and II). 61.17% of the group (n = 104) were men with mean age of 67.3 ± 9.1 years. In this group coronary artery disease and acute coronary syndromes were significantly more prevalent, 27.1% (n = 58) vs. 7.4% (n = 25), p < 0.005, which could suggest more frequent ischemic etiology of mitral regurgitation in this group [21]. Angiographic images revealed that stenosis in LAD (26.7%, n = 56) and RCA (25.7%, n = 54) were the most frequent lesions. Diagonal artery stenosis was significantly more common than in other valvular diseases (14.2% (n = 30) vs. 3.2% (n = 11), p < 0.001) (Table III). Percutaneous coronary angioplasty was performed in 22.8% (n = 48) of patients with severe mitral valve insufficiency vs. 21.19% with other valvular diseases (Table III). 38.4% of patients with mitral valve insufficiency underwent cardiac surgery (group with other valvular diseases 49.6%, p = 0.035) with a combined procedure in every fourth patient.

Fifty-four percent of study subjects underwent surgery, with the highest prevalence of aortic stenosis (81.3%), which was significantly higher than in the rest of the group (p < 0.001). TAVI was performed in 9 cases; in single cases the procedure was combined with planned PCI (n = 6) (Table IV).

In the National Registry of Cardiac Surgery Procedures, the most common are aortic stenosis procedures and surgical revascularization, often in patients with coexisting mitral regurgitation. Multi-valve operations constituting over 10% of all cardiosurgical procedures [22]. Roques et al. reported 67.3% of aortic valve procedures and 41.8% of mitral valve operations. CABG was performed in 20% of cases. In the study of Ghosh two-valve procedures represented 10% of all cases, and 32% patients had a valvular operation combined with CABG [11, 14].

52.7% (n = 540) of patients with valvular heart disease died during the follow-up (n = 1025), regardless of the severity of the defect. The comparison of patients who survived and died found that higher mortality occurred in the group of patients with severe mitral regurgitation, 62.9% (n = 132) vs. 37.1% (n = 78), p < 0.001. Patients who died more often had significant stenoses in coronary arteries and acute coronary syndromes. Such interdependence was not observed in case of non-significant coronary artery lesions. The independent mortality risk factors were: age (OR = 1.038; 95% CI: 1.005–1.072; p = 0.022) and aortic regurgitation (OR = 2.39, 95% CI: 5.370–11.065; p = 0.035). In the current literature mortality risk factors in patients with valvular heart disease are: age, type and stage of progression of the valvular defect, low ejection fraction of the left ventricle, coexistence of coronary artery disease, high NYHA class, hypertension, diabetes, chronic kidney disease and pulmonary hypertension. Perioperative risk in patients with valvular heart disease increases with the necessity of additional

### Table IV. Percutaneous coronary interventions and cardiac procedures during follow-up

| Parameter          | Patients with severe AVS (N = 715) | Patients with severe MVI (N = 968) | Patients with severe MVS (N = 33) | Patients with severe MVI + MVS (N = 999) | Patients with severe MVI + MVS + AVS (N = 206) | Patients with severe AVS (N = 739) | Patients with severe AVS + MVI (N = 968) | Patients with severe AVS + MVI + MVS (N = 31) | Patients with severe AVS + MVI + MVS + VR (N = 793) | Patients with severe AVS + MVI + MVS + VR + CABG (N = 540) |
|--------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------------|---------------------------------------------|-----------------------------------|------------------------------------------|---------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| PCI                | (W = 26) 7.4% (9.1%)              | (W = 74) 7.6% (9.1%)              | (W = 12) 5.8% (11.2%)            | (W = 99) 9.2% (12.9%)                   | (W = 25) 9.4% (12.0%)                      | (W = 97) 5.8% (9.2%)                  | (W = 72) 0.6% (11.2%)                    | (W = 9) 0.6% (11.2%)                         | (W = 27) 5.8% (9.2%)                           | (W = 284) 5.8% (9.2%)                           |
| TAVI               | (W = 54) 7.5% (9.1%)              | (W = 54) 3.2% (9.1%)              | (W = 9) 0.0% (11.2%)            | (W = 56) 9.2% (12.9%)                   | (W = 31) 5.8% (9.2%)                      | (W = 42) 0.0% (11.2%)                  | (W = 9) 0.0% (11.2%)                       | (W = 9) 0.0% (11.2%)                         | (W = 42) 0.0% (9.2%)                           | (W = 554) 5.8% (9.2%)                           |
| Surgery            | (W = 56) 5.0% (9.1%)              | (W = 56) 8.1% (9.1%)              | (W = 31) 7.1% (9.2%)            | (W = 58) 9.2% (12.9%)                   | (W = 32) 7.1% (9.2%)                      | (W = 27) 5.0% (9.2%)                   | (W = 9) 0.0% (11.2%)                       | (W = 9) 0.0% (11.2%)                         | (W = 27) 5.0% (9.2%)                           | (W = 554) 5.8% (9.2%)                           |
| Percutaneous coronary interventions and cardiac procedures during follow-up: VR – valve replacement, VR + CABG – valve replacement and coronary artery bypass grafting.
syndromes more frequently than other valvular heart stenoses in coronary arteries and with acute coronary syndrome. Severe mitral insufficiency coexists with significant than severe mitral regurgitation in the Polish popula-
group of patients [27, 28].

Survival was 80% in the AVR group and 71% in the MVR
disease [26]. In a study of young adults mean 15-year
were age, kidney and lung disease, and coronary artery
disease [24]. In the studies conducted during a similar pe-
iod, 20-year survival was estimated at 30% in patients
after aortic valve replacement, and 20% after mitral valve
replacement [25]. Peterseim et al. reported 10-year sur-
prise mortality vs. 6.1% in mitral valve replace-
ments accounts for 10% of cases and is 2-fold higher
compared to a single valve operation [23]. A British reg-
istry with data collected between 2004 and 2008 pres-
ents periprocedural mortality in aortic valve procedures
at the level of 2.8%. Mitral valve repairs resulted in 2% periprocedural mortality vs. 6.1% in mitral valve replace-
ments [24]. In the studies conducted during a similar pe-
riod, 20-year survival was estimated at 30% in patients
after aortic valve replacement, and 20% after mitral valve
replacement [25]. Peterseim et al. reported 10-year sur-
vival in half of cases. Independent mortality risk factors
were age, kidney and lung disease, and coronary artery
disease [26]. In a study of young adults mean 15-year
survival was 80% in the AVR group and 71% in the MVR
group of patients [27, 28].

Conclusions

Severe aortic stenosis is becoming more prevalent than severe mitral regurgitation in the Polish popula-
tion. Severe mitral insufficiency coexists with significant stenoses in coronary arteries and with acute coronary syndromes more frequently than other valvular heart diseases. Coronary artery disease is one of the most significant factors worsening the prognosis of patients with acquired heart diseases. LAD stenosis is the most common lesion in the coronary arteries, while severe stenosis of the diagonal artery occurs more often in mitral insufficiency. Non-significant lesions and marginal branch stenosis had no influence on survival. Acute cor-
ony syndrome is an additional burden in the group of patients with valvular heart diseases. The independent risk factors for death were coexisting aortic valve insuffi-
ciency and age. The worst prognosis was in the group
of patients with severe MVI, which may result from high-
branch stenosis had no influence on survival. Acute cor-
ony syndrome is an additional burden in the group of patients with valvular heart diseases. The independent risk factors for death were coexisting aortic valve insuffi-
ciency and age. The worst prognosis was in the group
of patients with severe MVI, which may result from high-
Conflict of interest

The authors declare no conflict of interest.

References

1. Strzelecki Z, Szymborski J. Zachorowalność i umieralność na choroby układu krążenia a sytuacja demograficzna Polski. 2015; 1–28. Available at: https://bib.stat.gov.pl/files/gfx/bib/pl/zamowieniapubliczne/426/248/1/81_gp_rrl_2015_monografia_kardiologiczna.pdf.
2. Ray S. Changing epidemiology and natural history of valvular heart disease. Clin Med 2010; 10: 168-71.
3. Iung B, Baron G, Butchart EG, et al. A prospective survey of pa-
tients with valvular heart disease in Europe: The Euro Heart Sur-
vey on valvular heart disease. Eur Heart J 2003; 24: 1231-43.
4. Hryniewiecki T, Stępińska J. WadPol – POLKARD. Ogólnopolski Rejestr Nabytech Wad Zastawkowych. Kardiol Pol 2009; 67; W169 (abstr.).
5. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Failure 2012; 14: 803-69.

Figure 2. Comparison of dead and alive patients (only significant differences presented, p < 0.05)

AVI – aortic valve insufficiency, CAD – coronary artery disease, Cx – circumflex artery, Diag – diagonal artery, LAD – left anterior descending, LM – left main artery, NSTEMI – non ST elevation myocardial infarction, MVI – mitral valve insufficiency, STEMI – ST elevation myocardial infarction, RCA – right coronary artery.
6. Departament Badań Demograficznych GUS. Prognoza ludności Polski na lata 2008-2035. Główny Urząd Statystyczny. 2018; 147-190. Available at: https://stat.gov.pl/cps/rde/xbcr/gus/l prognoza_ludnosci_na_lata2008_2035.pdf.

7. Toggweiler S, Zuber M, Sunder D, et al. Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: durability of the procedure and predictors of outcome. Open Heart 2014; 1: e000056.

8. Moat NE, Ludman P, De Belder M, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: The UK TAVI (United Kingdom transcatheter aortic valve implantation) registry. J Am Coll Cardiol 2011; 58: 2130-8.

9. Mohr FW, Holzhey D, Möllmann H, et al. The German Aortic Valve Registry: 1-year results from 13 680 patients with aortic valve disease. Eur J Cardiothorac Surg 2014; 46: 1-9.

10. Departament Badań Demograficznych GUS. Ludność według płci, województwa i podregionów 2016. Available at: http://demografia.stat.gov.pl/bazademografia Accessed February 28, 2019.

11. Ghosh P. Changing trends in valve surgery in Europe: 1991-2000. J Heart Valve Dis 2004; 13: 1-10.

12. Giannoglou GD, Antoniadis AP, Chatzizisis YS, et al. Difference in the topography of atherosclerosis in the left versus right coronary artery in patients referred for coronary angiography. BMC Cardiovasc Disord 2010; 10: 26.

13. Wasilewski J, Niedziela J, Osadnik T, et al. Predominant location of coronary artery atherosclerosis in the left anterior descending artery. The impact of septal perforators and the myocardial bridging effect. Kardiochir Torakochir Pol 2015; 12: 379-85.

14. Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 15: 813-6.

15. Edwards FH, Peterson ED, Coombs LP, et al. Prediction of operative mortality after valve replacement surgery. J Am Coll Cardiol 2001; 37: 885-92.

16. Hamamoto M, Bando K, Kobayashi J, et al. Durability and outcome of aortic valve replacement with mitral valve repair versus double valve replacement. Ann Thorac Surg 2003; 75: 24-8.

17. Mihaljevic T, Lam BK, Rajeswaran J, et al. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol 2007; 49: 2191-201.

18. Niedziela J, Osadnik T, Rodele M, et al. Atherosclerotic plaque burden distribution in the coronary arteries. The myocardial bridging effect. Choroby Serca Naczyń 2015; 12: 19-24.

19. Lee S, Choi EK, Chang Hl, et al. Subclinical coronary artery disease as detected by coronary computed tomography angiography in an asymptomatic population. Korean Circ J 2010; 40: 434-41.

20. Enrico B, Suranyi P, Thilo C, et al. Coronary artery plaque formation at coronary CT angiography: morphological analysis and relationship to hemodynamics. Eur Radiol 2009; 19: 837-44.

21. Mihaljevic T, Lam BK, Rajeswaran J, et al. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol 2007; 49: 2191-201.

22. Maruszewski B TZ. Raport Krajowego Rejestru Operacji Kardiochirurgicznych KROK-POLKARD. 2016. Available at: www.krok. org.pl.